aTyr Pharma reports Q4 EPS (21c), two estimates (22c)
As of December 31, 2018, aTyr had $49.5M in cash, cash equivalents and investments and 42M shares of common stock outstanding on an if-converted basis. "We continue to execute our clinical development plan for our lead therapeutic candidate, ATYR1923, while also entering into meaningful collaborations with both academic institutions and global drug development partners that leverage our novel tRNA synthetase biology," said Sanjay Shukla, president and CEO of aTyr. "We initiated our Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients in December 2018 as planned, and look forward to interim results in the fourth quarter of 2019. Data from this study represents a significant potential inflection point for our Company, and will guide future development in pulmonary sarcoidosis. We are pleased with the initial conduct of this study and look forward to sharing interim results later this year."